Autres langues

06/08 Emcure Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026
06/08 Emcure Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
06/08 Emcure Pharmaceuticals Limited Announces Board and Management Changes
21/07 Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026
21/07 Emcure Pharmaceuticals Limited completed the acquisition of an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh.
20/07 Emcure Pharmaceuticals Limited Expands Use Of Poviztra For MASH Indication Following CDSCO Approval
13/07 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from its shareholders.
13/07 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh.
03/07 Emcure Pharmaceuticals Unit to Acquire Remaining Shares in Canada's Mantra Pharma for C$50 Million
30/06 Emcure Pharmaceuticals Limited Announces Superannuation of Kuber Jagdale from President ? API Business, Effective June 30, 2026
06/05 Emcure Pharmaceuticals Scouts for M&As
05/05 Emcure Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026
05/05 Emcure Pharmaceuticals March-quarter consol net profit 2.43 billion rupees
04/05 Mauritius' BC Investments offloads shares in Indian drug maker Emcure
07/04 Apollo Tyres Ltd. Announces Resignation of Berjis Desai as Independent Director, Effective April 7, 2026
02/03 Emcure Pharmaceuticals and Roche sign distribution agreement in India
02/03 Emcure Pharmaceuticals Limited and Roche Sign Distribution Agreement to Strengthen Nephrology and Transplant Care in India
09/02 Emcure Pharma Reports Fire Incident at Pune Manufacturing Plant
04/02 Emcure Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025
04/02 Emcure Pharmaceuticals Dec-quarter Consol Net Profit 2.31 Billion Rupees
04/02 Emcure Pharmaceuticals Limited Appoints Amruta Jana Yangalwar as Company Secretary and Compliance Officer, Effective February 4, 2026
31/01 Delhivery Limited Announces Board Changes
29/01 Emcure Pharmaceuticals Witnesses a Growth Spurt
20/01 Sun Pharma Announces Sana Shaikh Takes Charge as Head of Marketing
09/01 37,959,271 Equity Shares of Emcure Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 9-JAN-2026.
Aucun résultat pour cette recherche
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT